Neurogene Inc. (NGNE) stock
NGNENasdaqPharmaceutical PreparationsFiscal year ends December 31
$22.15−0.78 (-3.40%)
Close on Nov 20, 2026Market cap $443.25MP/E –Yield –
Neurogene free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Neurogene's free cash flow for the twelve months ending Jun 30, 2026 was -$87.71M. For fiscal 2025 it was -$78.36M. The highest annual figure on record is -$7.24M in fiscal 2012.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$78.36M | – |
| FY2024 | Dec 31, 2024 | -$71.41M | – |
| FY2023 | Dec 31, 2023 | -$51.74M | – |
| FY2022 | Dec 31, 2022 | -$55.05M | – |
| FY2021 | Dec 31, 2021 | -$50.82M | – |
| FY2020 | Dec 31, 2020 | -$26.79M | – |
| FY2019 | Dec 31, 2019 | -$16.27M | – |
| FY2018 | Dec 31, 2018 | -$31.63M | – |
| FY2017 | Dec 31, 2017 | -$45.21M | – |
| FY2016 | Dec 31, 2016 | -$30.94M | – |
| FY2015 | Dec 31, 2015 | -$20.29M | – |
| FY2014 | Dec 31, 2014 | -$17.60M | – |
| FY2013 | Dec 31, 2013 | -$7.83M | – |
| FY2012 | Dec 31, 2012 | -$7.24M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$24.12M | – |
| Q1 FY2026 | Mar 31, 2026 | -$26.40M | – |
| Q4 FY2025 | Dec 31, 2025 | -$17.56M | – |
| Q3 FY2025 | Sep 30, 2025 | -$19.64M | – |
| Q2 FY2025 | Jun 30, 2025 | -$19.61M | – |
| Q1 FY2025 | Mar 31, 2025 | -$21.55M | – |
| Q4 FY2024 | Dec 31, 2024 | -$17.61M | – |
| Q3 FY2024 | Sep 30, 2024 | -$15.73M | – |
| Q2 FY2024 | Jun 30, 2024 | -$16.35M | – |
| Q1 FY2024 | Mar 31, 2024 | -$21.72M | – |
| Q4 FY2023 | Dec 31, 2023 | -$17.10M | – |
| Q3 FY2023 | Sep 30, 2023 | -$11.65M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.41M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.58M | – |
| Q4 FY2022 | Dec 31, 2022 | -$19.37M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.61M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.53M | – |
| Q1 FY2022 | Mar 31, 2022 | -$14.54M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.56M | – |
| Q3 FY2021 | Sep 30, 2021 | -$9.34M | – |
| Q2 FY2021 | Jun 30, 2021 | -$14.47M | – |
| Q1 FY2021 | Mar 31, 2021 | -$14.45M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.88M | – |
| Q3 FY2020 | Sep 30, 2020 | -$599.00K | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.77M | – |
| Q1 FY2020 | Mar 31, 2020 | -$6.55M | -171.5% |
| Q4 FY2019 | Dec 31, 2019 | -$5.42M | – |
| Q4 FY2018 | Dec 31, 2018 | -$9.78M | – |
| Q3 FY2018 | Sep 30, 2018 | -$15.37M | – |
| Q2 FY2018 | Jun 30, 2018 | $9.15M | – |
| Q1 FY2018 | Mar 31, 2018 | -$15.63M | – |
| Q4 FY2017 | Dec 31, 2017 | -$11.62M | – |
| Q3 FY2017 | Sep 30, 2017 | -$11.56M | – |
| Q2 FY2017 | Jun 30, 2017 | -$10.65M | – |
| Q1 FY2017 | Mar 31, 2017 | -$11.39M | – |
| Q4 FY2016 | Dec 31, 2016 | -$9.09M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.74M | – |
See a number that looks wrong?